Your account is not claimed yet. You can sign up with ORCID to claim your account.

Silvia Di Agostino

ResearcherID Scopus Author ID Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 15

Top Venues

Journal of experimental & clinical cancer research : CR

Antioxidants (Basel, Switzerland)

Cancers

Biomedicines

Università degli Studi Magna Graecia di Catanzaro

Università degli Studi di Roma Tor Vergata Facoltà di Medicina e Chirurgia (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Università degli Studi Magna Graecia di Catanzaro Jun 12o 2020

Italy

Associate Professor :: Dep. of Health Sciences-Istology

Education History

Università degli Studi di Roma Tor Vergata Facoltà di Medicina e Chirurgia Jan 2o 1999 - May 10o 2002

Italy

PHD :: Department of Public Health and Cell Biology, Section of Anatomy

Publications

Vittoria Rago, Anna Perri, Silvia Di Agostino
New Therapeutic Perspectives in Prostate Cancer: Patient-Derived Organoids and Patient-Derived Xenograft Models in Precision Medicine. Biomedicines 11 (10) (2023)
Vittoria Rago, Silvia Di Agostino
Novel Insights into the Role of the Antioxidants in Prostate Pathology. Antioxidants (Basel, Switzerland) 12 (2) (2023)
Vittoria Rago, Silvia Di Agostino
Novel Insights into the Role of the Antioxidants in Prostate Pathology. Antioxidants (Basel, Switzerland) 12 (2) (2023)
Silvia Di Agostino, Valeria Canu, Sara Donzelli, Claudio Pulito, Andrea Sacconi, Federica Ganci, Fabio Valenti, Frauke Goeman, Stefano Scalera, Francesca Rollo, Anna Bagnato, Maria Grazia Diodoro, Enrico Vizza, Mariantonia Carosi, Beatrice Rufini, Orietta Federici, Manuel Giofrè, Fabio Carboni, Paola Muti, Gennaro Ciliberto, Sabrina Strano, Mario Valle, Giovanni Blandino
HSF-1/miR-145-5p transcriptional axis enhances hyperthermic intraperitoneal chemotherapy efficacy on peritoneal ovarian carcinosis. Cell death & disease 14 (8) (2023)
Vittoria Rago, Silvia Di Agostino
Novel Insights into the Role of the Antioxidants in Prostate Pathology. Antioxidants (Basel, Switzerland) 12 (2) (2023)
Silvia Di Agostino, Mahrou Vahabi, Chiara Turco, Giulia Fontemaggi
Secreted Non-Coding RNAs: Functional Impact on the Tumor Microenvironment and Clinical Relevance in Triple-Negative Breast Cancer. Non-coding RNA 8 (1) (2022)
Valentina Rocca, Giovanni Blandino, Lucia D'Antona, Rodolfo Iuliano, Silvia Di Agostino
Li-Fraumeni Syndrome: Mutation of TP53 Is a Biomarker of Hereditary Predisposition to Tumor: New Insights and Advances in the Treatment. Cancers 14 (15) (2022)
Giulia Fontemaggi, Chiara Turco, Gabriella Esposito, Silvia Di Agostino
New Molecular Mechanisms and Clinical Impact of circRNAs in Human Cancer. Cancers 13 (13) (2021)
Marco de Feo, Cristina De Leo, Umberto Romeo, Paola Muti, Giovanni Blandino, Silvia Di Agostino
Arenavirus as a potential etiological agent of odontogenic tumours in humans. Journal of experimental & clinical cancer research : CR 39 (1) (2020)
Valentina Panzeri, Isabella Manni, Alessia Capone, Chiara Naro, Andrea Sacconi, Silvia Di Agostino, Luisa de Latouliere, Andrea Montori, Emanuela Pilozzi, Giulia Piaggio, Gabriele Capurso, Claudio Sette
The RNA-binding protein MEX3A is a prognostic factor and regulator of resistance to gemcitabine in pancreatic ductal adenocarcinoma. Molecular oncology 15 (2) (2020)
Michal Shreberk-Shaked, Bareket Dassa, Sanju Sinha, Silvia Di Agostino, Ido Azuri, Saptaparna Mukherjee, Yael Aylon, Giovanni Blandino, Eytan Ruppin, Moshe Oren
A Division of Labor between YAP and TAZ in Non-Small Cell Lung Cancer. Cancer research 80 (19) (2020)
Antonella D'Amore, Ali Ahmed Hanbashi, Silvia Di Agostino, Fioretta Palombi, Andrea Sacconi, Aniruddha Voruganti, Marilena Taggi, Rita Canipari, Giovanni Blandino, John Parrington, Antonio Filippini
Loss of Two-Pore Channel 2 (TPC2) Expression Increases the Metastatic Traits of Melanoma Cells by a Mechanism Involving the Hippo Signalling Pathway and Store-Operated Calcium Entry. Cancers 12 (9) (2020)
Silvia Di Agostino, Giulia Fontemaggi, Sabrina Strano, Giovanni Blandino, Gabriella D'Orazi
Targeting mutant p53 in cancer: the latest insights. Journal of experimental & clinical cancer research : CR 38 (1) (2019)
Giovanni Blandino, Silvia Di Agostino
New therapeutic strategies to treat human cancers expressing mutant p53 proteins. Journal of experimental & clinical cancer research : CR 37 (1) (2018)
Magdalena Pruszko, Elisa Milano, Mattia Forcato, Sara Donzelli, Federica Ganci, Silvia Di Agostino, Simone De Panfilis, Francesco Fazi, David O Bates, Silvio Bicciato, Maciej Zylicz, Alicja Zylicz, Giovanni Blandino, Giulia Fontemaggi
The mutant p53-ID4 complex controls VEGFA isoforms by recruiting lncRNA MALAT1. EMBO reports 18 (8) (2017)

Silvia Di Agostino.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Silvia Di Agostino